Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Active, not recruiting
Aragon Pharmaceuticals, Inc.
Phase 1/Phase 2
2010-07-26
The purpose of this study is to assess the safety and activity of ARN-509 in men with
advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1
of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase
2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of
ARN-509.
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Active, not recruiting
Aragon Pharmaceuticals, Inc.
Phase 3
2013-10-14
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men
with high-risk non-metastatic castration-resistant prostate cancer.
This preview shows a limited data set Subscribe for full access, or try a Trial
Clinical Trials Update, Market Analysis, and Projection for Apalutamide
Last updated: January 26, 2026
Summary
Apalutamide, marketed as Erleada, is an androgen receptor inhibitor approved for prostate cancer treatment. Developed by Johnson & Johnson's Janssen, it has demonstrated efficacy in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). The drug's market expansion relies heavily on ongoing clinical trials, regulatory approvals, and evolving treatment paradigms. This report encapsulates recent clinical trial updates, evaluates current market trends, projects future market growth, and analyzes competitive positioning.
Clinical Trials Update
Recent and Ongoing Clinical Trials
Trial Name
Phase
Scope
Status
Enrollment (as of 2023)
Primary Endpoint
Key Results / Updates
SPARTAN (NCT01946204)
Phase 3
Non-metastatic CRPC
Completed
1,207
Metastasis-free survival (MFS)
Demonstrated significant MFS improvement; pivotal for approval in nmCRPC (2018)
PROSPER (NCT02200614)
Phase 3
nmCRPC
Completed
1,207
MFS
Confirmed superior MFS and overall survival (OS) benefits; basis for FDA approval
TITAN (NCT02919807)
Phase 3
Metastatic hormone-sensitive prostate cancer (mHSPC)
Ongoing
~1,006
Radiographic progression-free survival (rPFS)
Preliminary data suggest significant benefit; results expected in 2023–2024
ENZAMET (NCT02446405)
Ongoing
mHSPC
Ongoing
~1,125
Overall survival (OS)
Data expected 2024, assessing Apalutamide with androgen deprivation therapy (ADT)
ARMOR3-SV (NCT03313853)
Phase 3
Castration-resistant prostate cancer (mCRPC)
Recruiting
Not specified
Radiographic PFS
Evaluates safety and efficacy with novel combinations
Key Clinical Milestones (2022–2023)
Regulatory Approvals:
FDA (2018): Approval for nmCRPC based on SPARTAN trial.
EMA (2018): Similar approval.
Japan (2021): Approved for mCRPC post-chemotherapy or hormone therapy.
Emerging Data:
TITAN trial confirmed efficacy in mHSPC, broadening indications.
Enrollment expansions in combination therapy studies with immunotherapies and targeted agents.
Implications of Clinical Trials
The trajectory indicates a strategic expansion beyond nmCRPC into metastatic settings and combination therapies, potentially solidifying Apalutamide as a cornerstone in prostate cancer management.
Market Analysis
Current Market Size
Parameter
2022 Data
Source / Notes
Global prostate cancer drugs market
~$3.5 billion
[1]
Apalutamide sales (2022)
~$750 million
Johnson & Johnson Annual Report
Market share (prostate cancer drugs)
~21%
Based on Johnson & Johnson, Novartis, AstraZeneca data
Key Competitors and Market Shares
Drug
Mechanism
Market Presence
Approximate Share
Notes
Apalutamide (Erleada)
Androgen receptor inhibitor
Leading in nmCRPC & emerging in mHSPC
21%
First in class; FDA-approved 2018
Enzalutamide (Xtandi)
Androgen receptor inhibitor
Approx. 35%
Market leader overall
Darolutamide (Nubeqa)
Androgen receptor inhibitor
15%
Approved for nmCRPC, gaining ground
Market Drivers
Rising incidence of prostate cancer, projected to reach 1.4 million new cases globally by 2030[2].
Increasing adoption of novel hormonal agents (NHAs) due to improved survival.
Expansion of indications, especially in early-stage and combination therapy settings.
Growing prevalence of metastatic hormone-sensitive disease.
Barriers to Market Growth
Price and reimbursement constraints.
Competition from established drugs (Enzalutamide, Darolutamide).
Need for head-to-head comparative data to solidify positioning.
Market Projection (2023–2028)
Parameter
Projection
Source / Rationale
2023 Market Size (Global prostate cancer drug market)
~$4.1 billion
CAGR of ~6%, considering growth from new approvals
Apalutamide sales (2023–2028 CAGR)
+12% annually
Driven by new indications, combination therapies, expanded patient population
Market share (by 2028)
~25%
Assuming continued adoption in mHSPC and combination regimens
Projected Sales Breakdown (2023–2028)
Year
Estimated Sales (USD Million)
Assumptions
2023
~$860
Continued growth, initial expansion into mHSPC
2024
~$960
Further indication approvals, data from ongoing trials
2025
~$1.1 billion
Broad acceptance in combination therapies
2026
~$1.25 billion
Increased widespread adoption
2027
~$1.4 billion
Penetration into early metastatic disease
2028
~$1.56 billion
Market consolidation, competitive saturation
Competitive Positioning and Strategic Outlook
Strengths
First-in-class approval for nmCRPC.
Demonstrated manageable safety profile.
Broadening indications, including in metastatic settings.
Established manufacturer (Johnson & Johnson) with extensive distribution.
Weaknesses
Competition from enzalutamide and darolutamide with similar efficacy.
Patent expirations could impact pricing.
Limited data on efficacy in certain metastatic subsets.
Opportunities
Fast-track approvals for combination regimens.
Market entry into emerging markets with expanding prostate cancer prevalence.
Potential new formulations, such as extended-release tablets.
Threats
Competitive advancements from other pharmaceutical companies.
Pricing pressures and reimbursement caps.
Regulatory hurdles in emerging markets.
Comparison of Apalutamide with Competitors
Feature
Apalutamide
Enzalutamide
Darolutamide
Approval Year
2018
2012
2019
Approved Indications
nmCRPC, mHSPC (pending trials)
mCRPC, nmCRPC, mHSPC
nmCRPC, ongoing trials
Safety Profile
Mild to moderate side effects
Similar but with higher CNS effects
Favorable, fewer CNS side effects
Market Share (2022)
21%
35%
15%
Deep Dive into Future Clinical Impacts
Potential for Combination Therapies
Ongoing trials are assessing combinations with immune checkpoint inhibitors and PARP inhibitors.
Synergistic effects could redefine treatment algorithms.
Regulatory approvals for combination use could significantly uplift sales.
Regulatory Pathways
Accelerated approvals in emerging markets.
Priority review for new indications based on ongoing positive trial results.
Real-world evidence collection to supplement clinical data.
Key Takeaways
Apalutamide remains a pivotal drug for prostate cancer, especially following its initial success in nmCRPC.
Current clinical trials, notably TITAN and ARMOR3-SV, are expanding its therapeutic scope into mHSPC and mCRPC, respectively.
Market dynamics forecast continued growth driven by expanded indications, with projected sales reaching ~$1.56 billion by 2028.
Competition remains intense, requiring strategic positioning through combination therapies and clinical trial success.
Entering new markets and leveraging regulatory pathways will be critical to sustaining and growing market share.
FAQs
What are the primary indications for Apalutamide?
Apalutamide is approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and potentially expanding into metastatic hormone-sensitive prostate cancer (mHSPC) based on ongoing trials.
How does Apalutamide differ from its competitors?
It was the first androgen receptor inhibitor approved for nmCRPC and exhibits a manageable safety profile. It competes primarily with enzalutamide and darolutamide, with comparative efficacy data still emerging.
What are the upcoming clinical trials that could impact Apalutamide’s market?
The TITAN trial results will clarify its role in mHSPC, and ARMOR3-SV could extend its use in castration-resistant settings, fostering broader adoption.
Are there significant safety concerns with Apalutamide?
Overall, it demonstrates a manageable safety profile, with common side effects including fatigue, rash, and hypertension. CNS effects are less frequent compared to enzalutamide.
What strategic moves should pharmaceutical companies pursue for Apalutamide?
Focus on expanding indications via clinical trials, secure regulatory approvals in emerging markets, and develop combination regimens to enhance efficacy and market penetration.
References
Market Data & Prostate Cancer Drugs Market Size: Grand View Research, 2022.
Global Prostate Cancer Incidence: World Health Organization (WHO), 2021.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
